Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.